英文名稱 | Everolimus | RAD-001 |
---|---|
中文名稱 | 依維莫司 |
CAS號(hào) | 159351-69-6 |
分子式 | C53H83NO14 |
分子量 | 958.22 |
外觀 | White to off-white powder |
儲(chǔ)存條件 | Dry, dark and at 0 - 4 ℃ for short term (days to weeks) or -20 ℃ for long term (months to years). |
英文名稱 | Everolimus | RAD-001 |
---|---|
中文名稱 | 依維莫司 |
CAS號(hào) | 159351-69-6 |
分子式 | C53H83NO14 |
分子量 | 958.22 |
外觀 | White to off-white powder |
儲(chǔ)存條件 | Dry, dark and at 0 - 4 ℃ for short term (days to weeks) or -20 ℃ for long term (months to years). |
Everolimus, also known as RAD001, is a derivative of the natural macrocyclic lactone sirolimus with immunosuppressant and anti-angiogenic properties. In cells, everolimus binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate an immunosuppressive complex that binds to and inhibits the activation of the mammalian Target of Rapamycin (mTOR), a key regulatory kinase. Inhibition of mTOR activation results in the inhibition of T lymphocyte activation and proliferation associated with antigen and cytokine (IL-2, IL-4, and IL-15) stimulation and the inhibition of antibody production.
PMID: 20360931 PMCID: PMC2847314 DOI: 10.1593/tlo.09277
PMID: 19223496 DOI: 10.1158/1078-0432.CCR-08-2057
PMID: 29077243 PMCID: PMC5765289 DOI: 10.1111/cas.13431